Johns Hopkins has led psilocybin research, demonstrating safety and therapeutic potential in anxiety and smoking cessation, and has obtained regulatory approval to resume research with healthy volunteers.

Phase 3 trial data reviewed by the FDA show significant reductions in symptom severity for treatment‑resistant PTSD; trials are ongoing and FDA approval is pending.

This is a pre-approval access program (PAAP) for eligible participants.…